Page 42 - 2022_01-Haematologica-web

D. Qualls and G. Salles
highly refractory B-cell non-Hodgkin lym- phoma, including patients refractory to CAR T therapy. Blood. 2020;136(Suppl 1):42-43.
96. Feng M, Jiang W, Kim BYS, Zhang CC, Fu YX, Weissman IL. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019;19(10):568-586.
97. Advani R, Bartlett NL, Smith SM, et al. The first-in-class anti-CD47 antibody HU5F9-G4 + rituximab induces durable responses in relapsed/refractory DLBCL and indolent lymphoma: interim phase 1B/2 results. Hematol Oncol. 2019;37(S2):89-90.
98. Kim TM, Lakhani N, Gainor J, et al. ALX148, a CD47 blocker, in combination with rituximab in patients with non- Hodgkin lymphoma. Blood. 2020;136(Suppl 1):13-14.
99. Patel K, Ramchandren R, Maris M, et al. Investigational CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: update from the ongoing first-in-human dose escalation study. Blood. 2020;136 (Suppl 1):46-47.
100. Dheilly E, Moine V, Broyer L, et al. Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Mol Ther. 2017;25(2): 523-533.
101.Nakamura K, Casey M, Oey H, et al. Targeting an adenosine-mediated “don’t eat me signal” augments anti-lymphoma immu- nity by anti-CD20 monoclonal antibody. Leukemia. 2020;34(10):2708-2721.
102.Liu X, Pu Y, Cron K, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 201521(10):
1209-1215.
103. Laurent C, Charmpi K, Gravelle P, et al.
Several immune escape patterns in non- Hodgkin’s lymphomas. Oncoimmunology. 2015;4(8):e1026530.
104. Armand P, Janssens A, Gritti G, et al. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. 2021;137(5):637-645.
105. Ding W, Laplant B, Witzig TE, et al. PD-1 blockade with pembrolizumab in relapsed low grade non-Hodgkin lymphoma. Blood. 2017;130(Suppl 1):4055.
106. Salles G, Ghosh N, Lossos IS, et al. Atezolizumab in combination with obinu- tuzumab and lenalidomide demonstrates favorable activity and manageable toxicity in patients with relapsed/refractory follicular lymphoma (FL): an interim analysis of a phase Ib/II trial. Blood. 2018;132(Suppl 1):1603.
107. Palomba ML, Till BG, Park SI, et al. A phase IB study evaluating the safety and clinical activity of atezolizumab combined with obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphome (NHL). Hematol Oncol. 2017;35(S2):137-138.
108. Nastoupil LJ, Westin JR, Fowler NH, et al. Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study. J Clin Oncol. 2017;35(15_suppl):7519.
109. Houot R, Goldstein MJ, Kohrt HE, et al. Therapeutic effect of CD137 immunomod- ulation in lymphoma and its enhancement by Treg depletion. Blood. 2009;114(16):
3431-3438.
110. Gopal AK, Levy R, Houot R, et al. First-in-
human study of utomilumab, a 4- 1BB/CD137 agonist, in combination with rituximab in patients with follicular and other CD20+ non-Hodgkin lymphomas. Clin Cancer Res. 2020;26(11):2524-2534.
111. Segal NH, Logan TF, Hodi FS, et al. Results from an integrated safety analysis of ure- lumab, an agonist anti-CD137 monoclonal antibody. Clin Cancer Res. 2017;23(8):1929- 1936.
112. Timmerman J, Herbaux C, Ribrag V, et al. Urelumab alone or in combination with rit- uximab in patients with relapsed or refracto- ry B-cell lymphoma. Am J Hematol. 2020;95(5):510-520.
113. Xu Y, Szalai AJ, Zhou T, et al. FcgRs modu- late cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol. 2003;171(2):562- 568.
114.Herter S, Sam J, Ferrara Koller C, et al. RG6076 (CD19-4-1BBL): CD19-targeted 4- 1BB ligand combination with glofitamab as an off-the-shelf, enhanced T-cell redirection therapy for B-cell malignancies. Blood. 2020;136(Suppl 1):40.
115. Andorsky DJ, Coleman M, Yacoub A, et al. MAGNIFY phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent NHL. J Clin Oncol. 2020;38(15_suppl):8046.
116.Dreyling M, Santoro A, Leppä S, et al. Efficacy and safety in high-risk relapsed or refractory indolent follicular lymphoma patients treated with copanlisib. Hematol Oncol. 2019;37(Suppl):387-389.
34
haematologica | 2022; 107(1)